Contraception Clause Samples
Contraception. Certain FDA‐approved contraceptive methods, sterilization procedures, and patient education and counseling;
Contraception. The Service Provider is required to offer remote assessment and prescribing of contraception and arrange for the dispensing and supply of medication as described in this specification. Medication can be supplied via the post or for collection from a pharmacy. Customers can choose to purchase this component of service and it will therefore not be available to all Service Users. If this is not available, the Service Provider will signpost to other providers of contraception in that area (noting that this could include other e-services).
Contraception. The Proposer is using the following methods of contraception on an ongoing basis: .The Consenter is using the following methods of contraception on an ongoing basis: .The Consenter will use the following methods of contraception and/or protection during vaginal/anal* penetrative activities: .
Contraception. Food and Drug Administration-approved contraceptive methods, sterilization procedures, and patient education and counseling, not including abortifacient drugs”
Contraception. Study therapy may have adverse effects on a fetus in utero. It is not known if pembrolizumab has transient adverse effects on the composition of sperm. Female patients of reproductive potential must agree to use (or have their partner use) acceptable contraception during heterosexual activity to avoid becoming pregnant or impregnating a partner, respectively, while receiving study drug and for 120 days after the last dose of study drug. See Appendix B for acceptable methods of contraception. For this trial, male partners of female patients of child bearing potential will be considered to be of non-reproductive potential if they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition). Female patients will be considered of non-reproductive potential if they are either: • postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.); or • have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; or • has a congenital or acquired condition that prevents childbearing.
Contraception. Nonpregnant, nonlactating sexually active women of child bearing potential must agree to use a highly effective method of contraception from the Screening Visit until 16 weeks after final study drug administration. • Note: highly effective methods of contraception include: o hormonal contraceptives associated with inhibition of ovulation (stable dose for at least 4 weeks prior to first dose) o intrauterine device (IUD) o intrauterine system (IUS) o double barrier methods of contraception (barrier methods include male condom, female condom, cervical cap, diaphragm, contraceptive sponge) in conjunction with spermicide o tubal ligation o vasectomized male partner Sexually active male subjects must have documented vasectomy or must agree to use a highly effective method of contraception as defined above with their partners of childbearing potential from first dose until 16 weeks after final study drug administration. Protocol KPL-716-C202 CONFIDENTIAL and 10 indicating extremely difficult. This NRS will be used to assess subjects’ level of difficulty falling asleep from the Screening Visit through EOS Visit (Week 18). The difficulty falling asleep NRS is provided in the Daily NRS Tool Appendix 4.
Contraception. The Proposer is using the following methods of contraception on an ongoing basis:
Contraception females of childbearing potentia must use two forms of birth control, one being a barrier method (i.e., condoms, diaphragm, non-hormonal IUD) throughout the study and for at least 3 months after the final study drug dose. Hormonal contraception (estrogens stable ≥3 months) and hormonal IUDs are permitted if used with a secondary barrier birth control method (e.g., condoms).
Contraception. The Proposer is using the following methods of contraception on an ongoing basis: _____________________________________________________________________. The Proposer will use the following methods of contraception and/or protection during vaginal/anal* penetrative activities:
Contraception. Another factor which also does not have scientific agreement is the association between different contraception techniques and disease progression. One study found that implant contraception and injectables were protective of disease progression, while oral contraception was not (▇▇▇▇ et al., 2016). A systematic review agrees with the previous study that injectables were associated with protection of disease progression and oral contraception was not associated (▇▇▇▇▇▇▇▇, ▇▇▇▇▇, & ▇▇▇▇▇▇, 2016). This is contrary to another study which did not find an association between hormonal contraceptives (oral, IUDs, and DMPA) and disease progression among women who were not currently on ART (▇▇▇▇▇▇▇▇ et al., 2016).